Compare iShares Gold Trust (IAU) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs TransMedics Group Inc — how do they compare? iShares Gold Trust trades at $78.81 (market cap $61.51B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: iShares Gold Trust is far larger — about 22.4× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 3,206,729). Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 49 Days and TransMedics Group Inc for 24 Days on average.
| IAU | TMDX | |
|---|---|---|
Market Cap | $61.51B | $2.74B |
Volume | 3,206,729 | 949,331 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $150.42 |
52-Week Low | $74.21 | $61.99 |
Typical Hold Time | 49 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU stock trades at $78.87, up 2.35% today, but faces strong technical bearish signals with 13 of 13 moving averages indicating sell signals. The stock shows neutral momentum oscillators with RSI levels at 40.80 (6-day) and 31.31 (12-day) suggesting potential oversold conditions. Recent market sentiment reflects gold's sensitivity to interest rate expectations and Treasury yield movements.
Investment outlook remains cautious with technical indicators predominantly bearish and gold prices facing headwinds from rising yields. The stock's proximity to key support at $76-77 creates a critical level to watch, while Federal Reserve policy decisions on interest rates will likely drive near-term direction.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
